Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu

Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL) (CLL17)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04608318
Recruitment Status : Active, not recruiting
First Posted : October 29, 2020
Last Update Posted : February 23, 2023
Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON)
Nordic CLL Study Group (NCLLSG)
Swiss Group for Clinical Cancer Research (SAKK)
Cancer Trials Ireland
Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA)
Grupo Español de Leucemia Linfocítica Crónica (GELLC)
The Israeli CLL Study Group (ICLLSG)
Information provided by (Responsible Party):
German CLL Study Group

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : March 2027
Estimated Study Completion Date : March 2027